INHIBITING INFLUENCE OF INTERFERON- ALPHA ON THE LEVEL OF VASCULAR ENDOTHELIAL GROWTH FACTOR IN BLOOD SERUM OF BREAST CANCER PATIENTS UNDERGOING COMBINED THERAPY

Lisnyak I.I., Kudryavets Yu.I.

It has been shown, that introduction of interferon-alpha2b (IFN) into combined schemes of therapy of breast cancer patients (n = 89) determines the decrease of the number of cases of disease progression by 36.4–27.2% during 36 months of follow-up period dependent on the degree of lymph node metastasis (N0- N2). The VEGF baseline in blood serum of breast cancer patients is significantly higher than that in blood serum of healthy women (50 ng/ml) and varies from 264.7 ± 4.5 to 438.2 ± 6.8 ng/ml. VEGF level directly depends also on thedegreeof involvementof regional lymphnodesintumor progression — an increase of the number of lymph nodes metastases is accompanied by significant (p < 0.001) elevation of VEGF accumulation in blood serum. It has been shown that VEGF level became significantly elevated (p < 0.001) after radiotherapy and surgery of the breast cancer patients. Prolonged therapy with IFN at neoadjuvant and adjuvantregimens by developed schemes is accompanied with significant decrease (p < 0.001) of VEGFlevel. Incontrol groupofbreast cancer patients who did not receive IFN, VEGF level continued to be high up to the end of observation period. Retrospective analysis of the materials has shown that VEGF level correlates with clinical status of patients.